Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics

Shuang Xu, William F Jiemy, Elisabeth Brouwer, Janette K Burgess, Peter Heeringa, Kornelis S M van der Geest, Roser Alba-Rovira, Marc Corbera-Bellalta, Annemieke H Boots, Maria C Cid, Maria Sandovici*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Large-vessel vasculitides (LVV) comprise a group of chronic inflammatory diseases of the aorta and its major branches. The most common forms of LVV are giant cell arteritis (GCA) and Takayasu arteritis (TAK). Both GCA and TAK are characterized by granulomatous inflammation of the vessel wall accompanied by a maladaptive immune and vascular response that promotes vascular damage and remodeling. The inflammatory process in LVV starts in the adventitia where fibroblasts constitute the dominant cell population. Fibroblasts are traditionally recognized for synthesizing and renewing the extracellular matrix thereby being major players in maintenance of normal tissue architecture and in tissue repair. More recently, fibroblasts have emerged as a highly plastic cell population exerting various functions, including the regulation of local immune processes and organization of immune cells at the site of inflammation through production of cytokines, chemokines and growth factors as well as cell-cell interaction. In this review, we summarize and discuss the current knowledge on fibroblasts in LVV. Furthermore, we identify key questions that need to be addressed to fully understand the role of fibroblasts in the pathogenesis of LVV.

Original languageEnglish
Pages (from-to)103574
JournalAutoimmunity reviews
Publication statusE-pub ahead of print - 20-May-2024


Dive into the research topics of 'Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics'. Together they form a unique fingerprint.

Cite this